Patent 7928217 was granted and assigned to Alnylam Pharmaceuticals on April, 2011 by the United States Patent and Trademark Office.
This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.